Top Markets
#1 EXOD EXOD +22.08%
#2 XPIN Network XPIN Network +21.08%
#3 Neiro Neiro +19.61%
#4 Ontology Gas Ontology Gas +19.18%
#5 Geodnet Geodnet +17.15%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +15.58%
#7 Derive Derive +14.82%
#8 Status Status +14.44%
#9 Pons Pons +13.35%
#10 Ethena Staked ENA Ethena Staked ENA +10.96%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Rank in Stocks #25370
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Share Price
$2.63
Market Cap
$50.45M
Change (1 day)
-0.98%
Change (1 year)
78.10%
Country
JP
Trade Carna Biosciences, Inc. (4572)

Category

Healthcare
Stock price history for Carna Biosciences, Inc. (4572)
Highest end of day price: $2.33 on 2026-08-01

Lowest end of day price: $9.84 on 2008-03-01
Stock price history of Carna Biosciences, Inc. from 2008 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -2.66%
2025 11.27%
2024 -56.72%
2023 0.20%
2022 -48.88%
2021 -27.88%
2020 -39.08%
2019 101.34%
2018 -2.61%
2017 -38.05%
2016 -28.59%
2015 261.37%
2014 -16.25%
2013 159.13%
2012 -15.00%
2011 -31.55%
2010 -18.51%
2009 -1.93%
2008 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 35.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.21%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.33 -18.49%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 8.65%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 397.46%
US